Sutro Biopharma, Inc.’s Post

Finish Line Focus: Completing Your Oncology Case Report on Time

Exploring Obstacles in Fostering Patient Engagement Throughout Oncology Trials: Identifying and Acknowledging Industry Discrepancies Leave a message to connect with us and submit your blog for increased reach in your writing

At the 2024 ASCO Quality Care Symposium, new research revealed a sixfold increase in patients requiring drug switches due to payer step edits, with each switch costing practices $76 on average. Dr. Johnetta Blakely, EVP at Tennessee Oncology, emphasized the growing administrative strain these requirements place on healthcare providers, particularly in oncology. As drug regimens become more complex and overhead costs rise, the burden on physicians is leading to increased burnout and complicating patient care. Dr. Blakely warns that smaller community oncology practices may struggle to navigate these challenges, potentially impacting access to care in underserved areas. How can the industry address these rising concerns? #ASCOQuality2024 https://bit.ly/47VE1lx Tennessee Oncology Johnetta Blakely Community Oncology Alliance

In this recent blog, Vito Romita, Kim Watanabe and Meriam Djemai give an overview of how to prioritize patient needs in oncology #clinicaltrials, balancing complexities with a patient-centric approach. They examine how addressing enrollment and retention issues through strategies like increased patient access, reduced burden and managing logistics ensures effective trials and the promise of therapies for those who need them most. 📝 Read more » https://bit.ly/3ZFce6T

🌟De-risking Clinical Development in Precision Medicine for Oncology🌟 In the rapidly evolving field of oncology, precision medicine is transforming patient care and treatment outcomes. At ICON, we're committed to minimizing risks in clinical development, ensuring that innovative therapies reach patients efficiently and safely. 🔍 Key Insights: 1. Tailored Treatments: Precision medicine focuses on customizing treatment plans based on individual patient profiles, leading to more effective therapies. 2. Advanced Technologies: Utilizing cutting-edge tools and analytics helps streamline clinical trials, reducing time and cost while enhancing data quality. 3. Collaborative Approach: Engaging with a network of experts across various disciplines ensures comprehensive strategies that address the complexities of oncology research. Read our whitepaper to learn how to de-risk biomarker selection and implementation. https://ow.ly/hSs750TFGLf #Oncology #ClinicalDevelopment #Biotech #Innovation #PatientCare

Did you know, in the ecosystem of oncology treatment and decisions, Oncology Nurses are a critical bridge between physicians and patients? When conducting market research, nurses are often under-utilised as respondents, but their voice and perspective can inform deep insights across exploratory, communications, and tactical research objectives. In our latest piece, Senior Vice President and Global Head of HRW OR:BIT, Elizabeth George shares the importance of oncology nurses patient-carer relationship in supporting market research. Scroll through the carousel to find out more! #oncology #oncologytreatment #cancer #cancercare #HCPs #patients #patient #patientjourney #productlifestyle #oncologynurses #oncologypatients #carousel #didyouknow #patientrelationships #patientexperience #marketresearch #pharmamarketresearch #pharmaresearch #pharmaceutical #pharma #healthcaremarketresearch #marketresearch #healthcare #MRX

🔬 Oncology clinical trial participants bear significant burdens. It's crucial for professionals planning studies to prioritize their well-being. Patients, often unwell even before trials start, are impacted by every aspect—including required technologies. One solution? Prioritize patient-centered tech. 📊 Join this upcoming webinar with YPrime, where a former participant and cancer survivor, now a pharmaceutical R&D leader, shares her journey. Panelists will explore patient technologies like eCOA and connected devices, emphasizing how positive patient experiences benefit all stakeholders 🔗 REGISTER HERE: https://buff.ly/4a9pGC9 🌟 Featured speakers: Rosie Filling Donna Mongiello, RN, BSN Terry Rehm #DrugDevelopment #ClinicalResearch #Oncology #ClinicalData #OncologyTrials #eCOA #TherapeuticAreas #eCOATechnology

Clinical pathways have become a critical decision-support tool to help standardize evidence-based care and manage rising cancer care cost. In a recent article for Fierce Biotech, I explored the key implications, challenges, and opportunities for biopharma companies in the evolving clinical pathways landscape. Check out the full article below. https://lnkd.in/gPvC2RnS

Excellent overview of how growing clinical pathways exposure impacts pharmaceutical companies and the steps required to ensure appropriate access of new therapeutic uses to patients. This expert perspective from my Partner Sophia Xin Tan, PhD is worth a read.